Work

Abstract P2-06-02: Development of a first-in-class small molecule inhibitor (EC359) targeting oncogenic LIF/LIFR signaling for the treatment of triple negative breast cancer

Year: 2019

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.sabcs18-p2-06-02

Authors: S Viswanadhapalli, Y Luo, GR Sareddy, B Santhamma, M Zhou, M Li, UP Pratap, KA Altwegg, X Li, U Srinivasan, S Ma, A Chang, AC Riveros, KY Zhang, KV Dileep, X Pan, R Murali, M Bajda, G Raj, A Brenner, V Manthati, M Rao, RR Tekmal, HB Nair, KJ Nickisch, RK Vadlamudi

Institutions: Jagiellonian University, Cedars-Sinai Medical Center, RIKEN Center for Biosystems Dynamics Research, Evestra (United States), Mays Cancer Center at UT Health San Antonio, The University of Texas Southwestern Medical Center

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2944236452

Cites:

Cited by:

Related to: 10